STAT3 and neoplasm: Gupta et al found that miR-144/199-targeting transcripts of the mesenchymal proteoglycan Versican inhibits multiple myeloma by downregulating FAK/STAT3 signal, indicating that miR-144 also affects the FAK/STAT3 signaling pathway, potentially playing the role of tumor suppressor in multiple myeloma as well [23].